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1. Introduction and Aims 
 
1.1. Diversity of the non-neuronal cell compartment of the CNS 
Resident macrophages in the central nervous system (CNS) are key players in CNS homeostasis 
and during CNS pathology. In the brain, this cellular compartment comprises parenchymal 
microglia and non-parenchymal macrophages that reside in the perivascular (Virchow-Robin) 
spaces, choroid plexus, and meningeal compartments [Prinz & Priller 2014]. Brain macrophages 
play critical roles in regulation of immune responses at the boundaries and in the parenchyma of 
both healthy and diseased brain. In addition, microglia are involved in the clearance of apoptotic 
neurons and the refining of synaptic connectivity, and thus play an important role in maintaining 
CNS integrity and function [Sierra et al., 2010; Parkhurst et al., 2013]. Other brain macrophages 
sense danger signals at brain interfaces such as the blood-brain barrier (BBB; perivascular 
macrophages) or the blood-cerebrospinal fluid barrier (choroid plexus macrophages). Brain 
microglia originate from yolk sac-derived precursors that enter the CNS during early embryonic 
development. Under homeostasis, microglia expansion depends on local self-renewal of the 
resident population throughout life [Ginhoux et al., 2010; Kierdorf et al., 2013; Schulz et al., 2012; 
Ajami et al., 2011; Ajami et al., 2007; Saederup et al., 2010; Mizutani et al., 2012]. Likewise, the 
other CNS macrophage populations (these are meningeal, perivascular and choroid plexus 
macrophages) are also derived from yolk sac precursor, which largely relied on similar 
transcription factors such as PU.1 [Goldmann et al., 2016]. Similarly, the retina is populated by 
both perivascular macrophages and parenchymal microglia. Although the contribution of microglia 
in retinal homeostasis remains unclear, they are a key regulator in a variety of retinal diseases 
[Rathnasamy et al., 2019].  
During CNS diseases, hematogenous cells such as monocytes can enter the CNS, differentiate into 
brain parenchymal and/or non-parenchymal macrophages. On the one hand, these cells share some 
phenotypical characteristics with the resident macrophage population, on the other hand, their 
phenotypes are slightly differ from parenchymal microglia. For example, the monocyte-derived 
macrophages can be characterized as CD45hiCD11c+F4/80+MHCII+, whereas the parenchymal 
microglia are CD45loCD11cloF4/80loMHCII- [O’Koren et al., 2016]. Moreover, resident and 
hematogenous brain macrophages differentially contribute to local immune responses and the 
regulation of CNS inflammation [Hoogerbrugge et al., 1988; Priller et al., 2001; Corti et al., 2004; 
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Malm et al., 2005; Priller et al., 2006; Simard et al., 2006; Solomon et al., 2006; Djukic et al., 2006; 
Schechter et al., 2009; Derecki et al., 2012]. It has been suggested in mouse models of 
neurodegenerative disorders that hematogenous brain macrophages engrafted preferentially at the 
lesioned sites of the brain provide therapeutic advantages over resident populations [Simard et al., 
2006; Corti et al., 2004; Derecki et al., 2012; Hoogerbrugge et al., 1988; Schechter et al., 2009]. 
Whether the monocytes can also target the damaged retina and provide such therapeutic potential 
remains to be investigated. Furthermore, the above-mentioned findings are obtained from mouse 
models of neurodegenerative diseases that were applied to total body irradiation (TBI) and bone 
marrow (BM) transplantation. In these mouse models, the immune compartment of the recipients 
is diminished and, subsequently, TBI-induced brain damage triggers the engraftment of 
transplanted BM-derived cells, independently of neurodegenerative conditions [Mildner et al. 
2007], thus the migratory capability of hematogenous cells to the CNS remained questioned. 
Therefore, to precisely determine engraftment potential of peripheral cells into the CNS, an 
experimental protocol avoiding lethally irradiation and systemic collapse of host immunity is 
required.  
Importantly, spatially heterogeneity and functional differences between resident brain 
macrophages, in particular microglia, has been displayed at mRNA level in the mouse brains 
[Grabert et al., 2016]. These differences may explain region-dependent vulnerability of microglia 
and regional differences in the involvement in neurological and psychiatric diseases. In human, 
overall transcriptomic signature of microglia has been provided [Gosselin et al. 2017 & Galatro et 
al. 2017] at the bulk system analysis. However, a comprehensive profiling of human microglia 
transcriptomes and phenotypes at the single-cell level has remained to be investigated. In general, 
the phenotypic profiling on the basis of marker protein expressions on human microglia relied on 
either immunohistochemistry of post-mortem brain tissue or flow cytometric analysis of acutely 
isolated microglia cells [Melief et al. 2016, Mizee et al. 2017, Mildner et al. 2017, Moore et al. 
2015]. However, these approaches are limited to the high autofluorescent background of post-
mortem tissue and the limitation of investigated markers that can be simultaneously analysed in 
one measurement (generally less than 20). To unravel the phenotypic and functional diversity of 
the macrophage/microglial compartment of the CNS and to investigate how they interact with other 
CNS cells, a comprehensively high-dimensional analysis at the single-cell level is required. Better 
understanding of the phenotypic and functional differences between CNS macrophage populations, 
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as well as the differences between brain regions, may have clinical implications for the treatment 
and diagnosis of neurological and psychiatric disorders. 
 
1.2.  Mass spectrometry (MS) techniques in neurosciences  
MS techniques are widely applied for the elucidation, identification and quantification of 
molecules, including proteins. MS determines the mass-to-charge ratio of ionized species of 
molecules in simple and/or complex samples. MS can be applied to a broad spectrum of research 
fields and applications, including proteomics and metabolomics in neurosciences.  
As previously described in 1.1., the CNS hosts various cell types including neurons, glial cells and 
infiltrating immune cells, studying dynamic changes of CNS cell phenotypes and functions requires 
high-dimensional single-cell analytical methods. A complementary method for cell identification 
and quantification is needed to better understand cellular heterogeneity of the CNS during disease 
pathogenesis and progression. Cytometry by Time-of-Flight (CyTOF) or mass cytometry, a cell 
profiling technique that combines metal isotope-labelling technology, flow cytometric analysis 
with time-of-flight mass spectrometry, has been introduced for the real time high-dimensional 
single-cell immune profiling [Bandura et al., 2009]. Using CyTOF technology, cellular targets are 
labelled with metal-conjugated antibodies, and detected and quantified by time-of-flight mass 




Figure 1 Mass cytometry in neurosciences. CNS cells are isolated from the brain tissue and 
subsequently stained with stable metal isotope-labelled antibodies. The antibody-labelled cell 
mixture can be then identified and quantitatively analysed by mass cytometry (CyTOF), a 
combination of flow cytometry and mass spectrometry techniques.  
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Taking advantage of the low signal overlap between metal isotopes, CyTOF allows the 
simultaneous cell identification and quantification on the basis of more than 45 marker targets on 
a single cell. This technique can also overwhelm difficulties of investigating samples with the high 
background signal such as the post-mortem brain samples. Data obtained from CyTOF 
measurement are processed and analysed in an unsupervised manner using algorithm-based data 
analysis.  
The combination of a comprehensive array of protein markers and unsupervised data analysis 
provides a powerful strategy for cellular identification and quantification in a complex system of 
the CNS. Of note, CyTOF is however not a high-throughput-omics technique, since only up to 40-
45 selected molecules can be simultaneously assessed, and CyTOF assesses cellular phenotypes 
and functions using an antibody-based approach, thus it is not really an un-biased method. 
Nonetheless, CyTOF analysis reveals the comprehensive information on phenotypes and functions 
at the single-cell level, which is to date the only high-dimensional array of protein markers that 
could greatly complement the transcriptomic signature of various cell types in the complex 
environment of the CNS. 
Apart from the cell phenotypic heterogeneity revealed by CyTOF, the real-time cellular responses 
to the environment as well as the cell-cell interaction are also crucial information needed to 
understand the maintenance and regulation of CNS function. This dynamic interaction can be 
assessed using for example a mass spectrometry technique – metabolomic analysis –. Unlike 
classical proteomics, metabolomics reveal the alteration of abundance and/or characteristics of the 
downstream metabolites in a dynamic system, which result from environmental, genomic and/or 
proteomic factors as well as disease conditions. Although the methodology is still limited as bulk 
system investigations, the information obtained from metabolomic analyses during disease 
progression can provide a functional readout of target cells at different states, which is invaluable 
complementary information to phenotypic information obtained from CyTOF analysis, and thus 
will facilitate the investigation of cell signalling and/or biomarkers specifically involved in disease 
pathogenesis or disease progression and severity.  
One of the methodological approaches to study metabolomics is the stable isotope-resolved 
metabolomics, a supervised investigation in which selected isotopically labelled metabolites are 
dynamically traced in order to unequivocally assess metabolic alterations of the selected signalling 
pathway [Patti et al., 2012a; Patti et al., 2012b]. To apply this analytical approach, the metabolic 
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or signalling pathways are pre-selected prior to labelling experiments. Subsequently, cells of 
interest are cultured in the medium containing the isotope-labelled precursors of the pre-selected 
pathway. After some hours/days in vitro, cells are harvested, isotope-labelled molecules yielded 
from the labelling experiment are then isolated and subsequently digested prior to elucidation and 
quantification using MS. 
The most well-known stable isotope-metabolomic analysis is the stable isotope labelling by amino 
acid in cell culture (SILAC). In SILAC experiments, cells are cultured in the medium containing 
stable isotope-labelled amino acids. Commonly, amino acids lysine and arginine such as 2H4-lysine 
with 13C6-arginine or 15N213C6-lysine and 15N413C6-arginine were used for the labelling 




Figure 2 Schematic representation of stable isotope-resolved metabolomics. Isolated CNS 
cells or CNS cell lines are cultured in the presence of stable isotope-labelled amino acid or 
precursors of the signalling pathway of interest. The resulting isotope-labelled protein is then 
isolated, digested and subsequently analysed by mass spectrometry with or without a pre-separation 
step.  
 
SILAC has been widely applied for the investigation of disease-associated changes in proteomic 
profiles during neurological and psychiatric diseases, including glioblastoma [Formolo et al., 2011; 
Kozuka-Hata et al., 2012; Narushima et al., 2016], ischemia [Llombart et al., 2016], Alzheimer’s 
disease [Klegeris et al., 2008; McGeer et al., 2010; Tan et al., 2014] and Parkinson’s disease [Sarraf 
et al., 2013], TDP-43 proteinopathy [Seyfried et al., 2010]. Various CNS cell types can be used for 
SILAC experiments, for example the brain endothelial cell line hCMEC/D3 [Llombart et al., 2016], 
neuroblastoma SH-SY5Y cell line [Klegeris et al., 2008; Gokhale et al., 2012], human induced 
pluripotent stem cell (hiPSC)-derived neurons [Brennand et al., 2015], primary murine microglia 
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[Pinho et al., 2017; Zhang et al., 2017; Zhang et al., 2016] or primary cultures of mouse cerebellar 
granule neurons [Thouvenot et al., 2012].  
For example, Brennand et al. (2015) performed a discovery study on an alteration of cellular 
proteomics during schizophrenia using SILAC quantitative proteomic mass spectrometry analyses. 
In this particular study, the hiPSC neuronal progenitor cells (NPCs) were differentiated from 
fibroblasts, and were subsequently cultured in isotope (13C15N)-enriched arginine and lysine. 
Protein including isotope-labelled protein was then isolated from the cultured cells. The protein 
identification, quantification and analyses were performed using mass spectrometry and 
proteomics data analysis platform. In the comparison with the hiPSC-NPCs from healthy controls, 
cells from four schizophrenia patients showed abnormal protein expressions related to cytoskeletal 
remodelling and oxidative stress. 
Similar to SILAC, other precursor molecules instead of amino acids can be applied in vitro and/or 
in vivo, to elucidate the metabolomic phenotypes of the target cells. In this particular case, the 
labelled molecules obtained from the labelling experiment are not necessary to be proteins. For 
example, to demonstrate evidence for endogenous morphine biosynthesis in human neuronal cells, 
the human neuroblastoma cells, SH-SY5Y, were cultured in the medium containing 18O-labelled 
oxygen (18O2), [ring-13C6]-tyramine, (S)-[1-13C,N-13CH3]-reticuline or [N-C2H3]-thebaine, the 
precursors of the morphine biosynthetic pathway [Poeaknapo et al., 2004]. After seven days in 
vitro, morphine (the final product) and other intermediates of the morphine biosynthetic pathway 
were isolated from the cultured SH-SY5Y cells and were further elucidated and quantified by gas 
chromatography coupled with ion-selective tandem MS (GC/MS/MS). The results showed specific 
incorporation of the 18O, 13C or 2H isotopes into endogenous morphine and it’s intermediates, thus 
unequivocally proved the capability of synthesizing morphine of human neuroblastoma cells 
[Poeaknapo et al., 2004] (Figure 3). 
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 Figure 3 Schematic representation showing two examples of stable isotope-resolved 
metabolomic experiments from Poeaknapo et. al. 2004. Incubation of SH-SY5Y cells in the 
presence of 18O-oxygen (A) or [ring-13C6]-tyramine (B) resulted in an incorporation of two atom 





This study attempts to reveal cellular complexity of the myeloid compartment of the CNS including 
the retina in mouse models, as well as in the human system. Furthermore, analytical protocols for 
phenotypic and functional characterization of neuronal and non-neuronal cells (in particular 
microglia) in the CNS during homeostasis and diseases shall be established and evaluated.  
First, the study aims to investigate the migratory and engraftment capability of peripheral cells into 
the retina of mouse models for retinal degeneration. It should prove whether the retina processes 
the cellular complexity similar to that was observed in the brain. An integration of blood-derived 
macrophages into the network of the retinal macrophages/microglia will be determined.  
Second, this study shall demonstrate an induction of the engraftment of blood-derived cells under 
an experimental protocol avoiding lethally irradiation and systemic collapse of host immunity, 
which may in the future serve as a tool to precisely evaluate the migratory capacity of the 
circulating cells into the CNS and/or as a tool for development of therapeutic strategy in CNS 
diseases. 
Finally, analogue to mouse models, heterogeneous phenotypes and functions of the human CNS 
cells will be investigated. In this study, exploratory experiments aim to comprehensively 
characterise various CNS cell types and their responses during diseases will be demonstrated 
utilizing multi-parameter analysis including mass spectrometry techniques such as mass cytometry 
and stable isotope-resolved metabolomics. 
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2. Selected own work 
Summary 
Microglia and brain macrophages are increasingly evidenced as key regulators in CNS 
development, homeostasis and pathology. A better understanding of the cellular dynamics and 
mechanisms that regulate microglial homeostasis and function will provide the means to 
manipulate these cells for therapeutic purposes.  
In the first section of the selected own works (2.1.), the cellular complexity of CNS myeloid 
compartment were unraveled using an adoptive transfer experiment with gene-modified bone 
marrow cells (2.1.1.), bone marrow transplantation in a mouse model of facial nerve axotomy 
(2.1.2.) or high-throughput techniques such as single-cell RNA sequencing (scRNA-Seq) (2.1.3.). 
These findings demonstrated that, followed CNS conditioning, bone marrow-derived cells are 
recruited to the CNS including the retina, preferentially to the lesioned sites of the CNS. These 
infiltrating bone marrow-derived macrophages stably integrated into the CNS myeloid cell 
compartment of the lesioned brain. Similarly, the results obtained from scRNA-Seq revealed spatial 
and temporal microglial heterogeneity in both mouse and human brain. In diseased brain, the 
composition of microglial sub-populations was altered, and their microglial signatures could be 
rapidly changed during neurodegeneration (such as facial nerve axotomy) and/or 
neuroinflammation (such as multiple sclerosis).  
In the second part of the selected own works (2.2.), microglial heterogeneity was investigated in 
human post-mortem brain tissue and fresh brain biopsies (2.2.1.) at the single-cell protein level. 
Again, these results highlight the cellular complexity of the CNS myeloid compartment including 
the microglia subpopulations described in the first section (2.1.), which complemented the 
transcriptomic signatures revealed by scRNA-Seq. Moreover, the findings translated mouse 
microglial phenotypes to the human system, emphasizing the translational potential of the 
methodology for further investigation in clinical applications. Besides single-cell phenotypic and 
functional characterization by mass cytometry, functions and metabolomics of CNS cells can be 
assessed using mass spectrometry. For this approach, the human neuroblastoma cell line SH-SY5Y 
was used for the establishment of the methodology (2.2.2.). The study demonstrated that the SH-
SY5Y cell line was capable of synthesizing targeted metabolites (in this case “morphine”). Briefly, 
SH-SY5Y cells were cultured in the presence of 13C-, 2H- or 18O-labelled precursors of the 
morphine biosynthetic pathway. SH-SY5Y cells de novo incorporate the stable isotope-labelled 
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precursors into endogenously synthesized morphine. The finding unequivocally proved the 
capacity of de novo morphine synthesis of human neuroblastoma cells. This established 
methodology can be applied for future metabolomic study of CNS cells including microglial cells.    
 
2.1.  Cellular complexity of CNS myeloid compartment 
2.1.1. Boettcher C, Ulbricht E, Helmlinger D, Mack AF, Reichenbach A, Wiedemann P, 
Wagner HJ, Seeliger MW, Bringmann A, Priller J. 
Long-term engraftment of systemically transplanted, gene-modified bone marrow-
derived cells in the adult mouse retina.  
Br J Ophthalmol, 92:272-275 (2008).  
http://dx.doi.org/10.1136/bjo.2007.126318 
 
The study provided evidence for the engraftment of BMDCs in the retina, preferentially around 
sites of retinal damage, and hence provided proof-of-principle of an application of BMDCs as 
vehicles for gene delivery to the retina.  
Similar to the brain, after retinal damage, BMDCs can be targeted to the retina, precisely into the 
inner (IPL) and outer (OPL) plexiform layers and the ganglion cell layer (GCL), as well as into 
the optic nerve (ON). These cells differentiated into retinal macrophages.  
These observations were also true for BMDCs that were transduced with a retroviral vector to 
express the enhanced green fluorescent protein (eGFP) prior to transplantation. The eGFP-
expressing BMDCs engrafted in the central retina (i.e. IPL, OPL and GCL), where the retinal 
vascular plexuses are present. Rarely, the gene-modified BMDCs were found in the inner nuclear 
layer (INL), but virtually none of them engrafted to the photoreceptor layer or retinal pigment 
epithelium (RPE). The engrafted cells were immunoreactive for the myeloid markers CD11b and 
Iba1, but did not express vimentin (marking astrocytes, retinal Müller glial cells and retinal 
horizontal cells), calbindin (marking retinal horizontal cells), PKCa (marking retinal bipolar cells) 
or NeuN (marking ganglion cells). Strikingly, the gene-modified BMDCs engrafted in the retina 
and expressed the delivered gene eGFP for up to 15 months after transplantation.  
In mouse models of retinal degeneration (i.e. rd1 mutant FVB/N mice and spinocerebellar ataxia 
type 7 mice), eGFP-expressing BMDCs were found at high frequency, predominantly at the sites 
of retinal degeneration both in central and peripheral retina. These cells also expressed the GSA 
lectin, a marker for activated microglia and macrophages. 
 
In sum, the findings provided evidence for the cellular complexity of the retinal myeloid 
compartment and the capability of BMDCs to enter the retina, in particular the degenerated retina. 




2.1.2.  Böttcher C, Fernández-Klett F, Gladow N, Rolfes S, Priller J.  
Targeting myeloid cells to the brain using non-myeloablative conditioning.  
Plos One, 8:e80260 (2013).  
https://doi.org/10.1371/journal.pone.0080260 
 
Besides microglia, brain macrophages are involved in the maintenance of brain homeostasis. In 
neurogenerative diseases like Alzheimer´s disease, brain macrophages are capable of 
phagocytosing b-amyloid, whereas the resident microglia seem to be ineffective in this function. 
Ontogenetically, microglia are derived from immature yolk sac macrophages that enter the brain 
during early embryogenesis, while brain parenchymal macrophages originate from bone marrow-
derived cells (BMDCs). Since the phenotypes of resident microglia and brain parenchymal 
macrophages are overlapping, it is challenging to distinguish between these two cell types.  
In this particular study, a mouse model of bone marrow transplantation (BMT) was used as a tool 
to study bone marrow-derived brain macrophages. Unlike the classical mouse model of BMT that 
uses total body irradiation (TBI) or chemotherapy for host conditioning prior to the transplantation 
of eGFP-expressing BMDCs, non-myeloablative focal head irradiation (HI) was applied in this 
study to target the BMDCs to sites of brain damage in mice. This mild treatment induced 
recruitment of BMDCs to the sites of motoneuron degeneration in the brainstem as early as 7 days 
after facial nerve axotomy despite much lower levels of blood chimerism (i.e. <5% of donor-
derived cells in the peripheral blood of the recipients) compared with TBI (>95%). Of note, the HI 
regimen showed comparatively lower inflammatory responses in the CNS than TBI or 
chemotherapy, as revealed by lower mRNA expression of CCL2, CXCL10, TNF-a and CCL5. The 
findings demonstrated that peripheral BMDCs can be targeted to the CNS, in particular after 
neuronal damage, even at the very low chimerism in the peripheral blood. At the sites of brain 
damage, these cells differentiated to brain parenchymal macrophages. The established conditioning 
regimen is an alternative protocol for recruiting BMDCs to the CNS with minimal disturbance of 
the hematopoietic compartment, and thus can be used to selectively study BM-derived brain 
macrophages in animal models of neurodegenerative diseases. 
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Abstract
Bone marrow-derived cells (BMDCs) are able to colonize the central nervous system (CNS) at sites of damage. This
ability makes BMDCs an ideal cellular vehicle for transferring therapeutic genes/molecules to the CNS. However,
conditioning is required for bone marrow-derived myeloid cells to engraft in the brain, which so far has been achieved
by total body irradiation (TBI) and by chemotherapy (e.g. busulfan treatment). Unfortunately, both regimens
massively disturb the host’s hematopoietic compartment. Here, we established a conditioning protocol to target
myeloid cells to sites of brain damage in mice using non-myeloablative focal head irradiation (HI). This treatment was
associated with comparatively low inflammatory responses in the CNS despite cranial radiation doses which are
identical to TBI, as revealed by gene expression analysis of cytokines/chemokines such as CCL2, CXCL10, TNF-α
and CCL5. HI prior to bone marrow transplantation resulted in much lower levels of blood chimerism defined as the
percentage of donor-derived cells in peripheral blood (< 5%) compared with TBI (> 95%) or busulfan treatment
(>50%). Nevertheless, HI effectively recruited myeloid cells to the area of motoneuron degeneration in the brainstem
within 7 days after facial nerve axotomy. In contrast, no donor-derived cells were detected in the lesioned facial
nucleus of busulfan-treated animals up to 2 weeks after transplantation. Our findings suggest that myeloid cells can
be targeted to sites of brain damage even in the presence of very low levels of peripheral blood chimerism. We
established a novel non-myeloablative conditioning protocol with minimal disturbance of the host’s hematopoietic
system for targeting BMDCs specifically to areas of pathology in the brain.
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Introduction
Microglia are the key immune effector cells of the central
nervous system (CNS), mediating local inflammatory and
innate immune responses. This CNS cell population has
recently been shown to derive from immature yolk sac
macrophages that infiltrate the brain during early
embryogenesis [1-3]. Thus, microglia are ontogenetically
distinct from hematopoietic stem cell (HSC)-derived tissue
macrophages that originate from the bone marrow continuously
throughout adult life. In line with these findings, no engraftment
of myeloid cells was observed in the CNS of parabiotic mice, in
which blood from two different animals is chronically shunted,
suggesting that circulating hematopoietic progenitors and
circulating monocytes do not significantly contribute to
microglia homeostasis after birth [1-5].
However, bone marrow-derived cells (BMDCs) are able to
colonize the adult CNS under certain conditions.
Transplantation of genetically labelled BMDCs into total body-
irradiated hosts has demonstrated that circulating myeloid cells
engraft in the CNS and contribute to the pool of brain
macrophages, both in the absence and during overt brain
pathology [6-21]. Irradiation-induced changes in the CNS, as
well as the introduction of hematopoietic stem/progenitor cells
into the circulation have been suggested as necessary
conditions for the recruitment of myeloid cells into the brain
[1,4,21].
In line with their different origin, bone marrow-derived
myeloid cells and microglia appear to exert differential
functions in the CNS. In a mouse model of Alzheimer’s
disease, myeloid cells were able to phagocytose β-amyloid,
whereas resident microglia appeared to be rather ineffective in
this task [13,14]. Similarly, BMDCs were found to attenuate or
even arrest pathology in mouse models of neuropsychiatric
disorders including Rett syndrome, amyotrophic lateral
sclerosis, Krabbe’s disease and Parkinson’s disease
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e80260
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[19,20,22,23]. Hence, myeloid cells have a tremendous
therapeutic potential for neurological and psychiatric diseases.
However, establishing a clinical conditioning regimen remains a
challenge. Although total body irradiation (TBI) is an effective
conditioning protocol to target the myeloid cells to the brain,
this myeloablative treatment induces massive CNS
inflammation and disturbance of the host’s hematopoietic
system [21,24]. Recently, conditioning with the alkylating
chemotherapeutic agent, busulfan, has been suggested as an
alternative [24]. Indeed, myeloablation with busulfan is being
used in the clinical setting [25]. However, myeloid cell
engraftment at sites of CNS damage after busulfan
conditioning in mice was either absent [26] or dramatically
reduced compared to irradiation [24].
Here, we established a protocol for CNS conditioning using
focal head irradiation (HI) that avoids myeloablation and
minimally disturbs the host’s hematopoietic system. Regardless
of the low presence of donor-derived cells in the peripheral
circulation, BMDCs rapidly and selectively engrafted at sites of
neurodegeneration. This conditioning regimen may serve as an
alternative protocol for targeting myeloid cells to the CNS with
minimal impairment of the hematopoietic compartment.
Materials and Methods
Mice
C57BL/6 wild type mice were purchased from Charles River
(Sulzbach). C57BL/6 mice expressing the enhanced green
fluorescent protein (GFP) under the control of β-actin promoter
(ACTβ-EGFP) [27] were obtained from breeding facility of
Charité. All recipient mice were 7-12 weeks old at the time of
bone marrow transplantation (BMT).
All animal experiments were performed in strict accordance
with national and international guidelines for the care and use
of laboratory animals (Tierschutzgesetz der Bundesrepublik
Deutschland, European directive 2010/63/EU, as well as GV-
SOLAS and FELASA guidelines and recommendations for
laboratory animal welfare). The experiments were specifically
approved by the committee on the ethics of animal experiments
of Berlin (Landesamt für Gesundheit und Soziales, Berlin,
Germany, Permit Number: G0364/10).
Conditioning
Mice were anesthetized by subcutaneous injection of a
mixture of ketamine (50 mg/kg) and xylazine (7.5 mg/kg) prior
to either total body irradiation (TBI) or focal head irradiation (HI)
with a single dose of 11Gy. Irradiation was performed using a
Caesium137 source (Gammacell 40 Exactor, Theratronics).
During HI, the body was protected from irradiation with lead
bars (3 cm thick). Dosimetric studies revealed a shielding
efficieny >90% (cumulative dose < 1 Gy in protected areas).
Busulfan-treated animals received two intraperitoneal (i.p.)
injections of 50 mg/kg busulfan (Busilvex®, Pierre Fabre
Pharma) at 5 and 3 days before BMT.
Bone marrow transplantation
After conditioning with either TBI or HI, wild type mice were
intravenously (i.v.) injected with 2 x 107 unsorted bone marrow
cells from ACTβ-EGFP mice within 24 hr after irradiation.
Animals were examined at 1, 2, 4 and 16 weeks post-
transplantation.
In the case of facial nerve axotomy (FNA), conditioning with
HI was performed at 2 weeks and with busulfan at 5 and 3
days prior to BMT (i.v. injection of 2 x 107 unsorted bone
marrow cells from ACTβ-EGFP mice). FNA was performed 24
hr before BMT and animals received daily i.p. injections of 2
mg/kg rapamycin (Enzo Life Science) thereafter. Groups with
HI or FNA alone served as controls. Animals were examined at
7 and 14 days post-transplantation.
Facial nerve axotomy
Facial nerve axotomy (FNA) was performed as described
previously [6]. Briefly, mice were anesthetized by
subcutaneous injection of a mixture of ketamine (50 mg/kg)
and xylazine (7.5 mg/kg). The right facial nerve was transected
at the stylomastoid foramen, resulting in ipsilateral whisker
paresis. The left facial nerve served as control.
Immunohistochemistry
Mice were anesthetized and perfused transcardially with cold
phosphate-buffered saline (PBS). Brains were dissected, post-
fixed in 4% paraformaldehyde (PFA) and cryoprotected with
30% sucrose. Coronal brain sections (30 µm) were obtained on
a cryostat.
Sections were blocked at room temperature for 1 hr with
20% normal goat/donkey serum (Biozol) in Tris-buffered saline
(TBS) containing 0.3% Triton X-100. After three washes in
TBS, sections were incubated with primary antibodies diluted
1:200 [anti-Iba-1 (Wako), anti-F4/80 (Invitrogen) or anti-GFP
(Nacalai Tesque, Invitrogen)] at 4°C overnight. After washing
with TBS, sections were incubated with Alexa-conjugated
secondary antibodies diluted 1:250 (Alexa 488-IgG and Alexa
594-IgG, Invitrogen) at room temperature for 3 hr. All
antibodies were diluted in TBS containing 1% normal goat/
donkey serum and 0.3% Triton X-100. Nuclei were
counterstained with 4,6-diamidino-2-phenylindole diluted
1:10,000 (DAPI, Sigma). The immunostained sections were
examined using a conventional fluorescence or laser-scanning
confocal microscope (Leica TCS SP5, Leica Microsystems).
Flow cytometric analysis
Spleens were excised and pushed through a 70-μm strainer,
bone marrow cells were flushed from both femurs and tibias.
All samples were collected in Dulbecco's PBS (Gibco)
containing 2% fetal bovine serum (Biochrom) and were stored
on ice during staining and analysis. Blood was collected from
the inferior vena cava using a citrate-coated syringe. Red blood
cells were lysed in Pharm LyseTM buffer (BD Biosciences).
Following Fc blocking, cells were stained with anti-CD115
(AFS98), Ly6C (AL-21), CD11b (M1/70), CD4 (RM4-5), CD8
(53-6.7), Ly6G (1A8) and CD19 (6D5). All antibodies were
purchased from Biolegend. Fluorescence-activated cell sorting
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(FACS) was performed using a Canto II (Becton Dickinson).
Forward- and side-scatter parameters were used for exclusion
of doublets from analysis. Data were analyzed with the FlowJo
software (TreeStar).
Quantitative real-time PCR (qPCR)
Animals were anesthetized and perfused transcardially with
cold PBS at 1, 2, 4 and 16 weeks after irradiation/BMT. Brains
were dissected and immediately shock-frozen in liquid nitrogen.
Total RNA was isolated from the brain using RNeasy Plus Mini
kit (Qiagen). RNA (approximately 2 µg) was transcribed into
cDNA using Amplitaq® DNA Polymerase kit (Applied
Biosystems, Roche). PCR reactions were carried out using the
LightCycler FastStart DNA Master Kit (Roche Molecular
Biochemicals) according to the manufacturer’s protocol. The
following primer pairs were used: CCL5 (forward 5’-TGC CCA
CGT CAA GGA GTA TTT-3’, reverse 5’-TCT CTG GGT TGG
CAC ACA CTT-3’), CXCL10 (forward 5’-TGC TGG GTC TGA
GTG GGA CT-3’, reverse 5’-CCC TAT GGC CCT CAT TCT
CAC-3’), TNF-α (forward 5’-CAT CTT CTC AAA ATT CGA
GTG ACA A-3’, reverse 5’-TGG GAG TAG ACA AGG TAC
AAC CC-3’) and CCL2 (forward 5’-TCT GGG CCT GCT GTT
CAC C-3’, reverse 5’-TTG GGA TCA TCT TGC TGG TG-3’).
qPCR was performed using a LightCycler 2.0 (Roche).
Statistical analysis
Results were analyzed with Prism 4.0 (GraphPad) and
statistical differences were evaluated using a non-paired
Student’s t test or one-way ANOVA with Posthoc Bonferroni
correction. Significance was accepted for p<0.05. Data are
shown as means ± SEM.
Results
Focal head irradiation induces delayed BMDC
engraftment in the brain
Irradiation has been described to be a necessary condition
for BMDC engraftment in the brain [21]. We hypothesized that
non-myeloablative conditioning using HI would induce CNS
microenvironment changes that suffice to trigger the
recruitment of circulating myeloid cells to the CNS in the
absence of full hematopoietic reconstitution. To this end, we
transplanted adult mice with unsorted GFP-expressing bone
marrow cells following either HI or TBI (Figure 1A). Thereafter,
we analyzed the induction of different cytokines and
chemokines in the brain (Figure 1B). Irradiation-induced
increases in gene expression of monocyte chemoattractant
protein-1 (MCP-1 or CCL2), interferon gamma-induced protein
10 (IP-10 or CXCL10), regulated on activation, normal T cell
expressed and secreted (RANTES or CCL5) and tumor
necrosis factor (TNF)-α were observed in the brains of both TBI
and HI mice (Figure 1B). However, the induction of CCL2 and
CXCL10 mRNAs was strongly reduced in HI compared with
TBI animals although the doses of radiation to the brain were
identical (Figure 1B). CCL5 and TNF-α mRNAs were also
reduced at 2 weeks after HI compared with TBI (Figure 1B).
As expected, chimerism (determined as the percentage of
GFP+CD45+ cells among all CD45+ cells) was significantly
lower in peripheral blood of HI mice compared with TBI animals
at 16 weeks post-BMT (TBI: 97 ± 0.6%, HI: 3 ± 0.3%; Figure
2A). When analyzing the brains of the chimeras, no donor-
derived GFP+ cells were detected up to 12 weeks after BMT in
HI animals, whereas TBI animals showed engraftment of
ramified BMDCs in all brain regions (data not shown). At 16
weeks after BMT, clusters of donor-derived GFP+ cells
appeared in the cortex of HI mice (Figures 2B,C). At this time
point, olfactory bulb, cortex and cerebellum were populated by
ramified GFP+ cells in the TBI group (Figures 2B,C).
Quantitative analysis revealed reduced BMDC engraftment in
the brains of HI mice compared with TBI animals (Figure 2B).
The numbers of ramified GFP+ cells were 5 ± 1/ mm2 (TBI)
versus 0/ mm2 (HI) in the olfactory bulb, 25 ± 1/ mm2 (TBI)
versus 5 ± 1/ mm2 (HI) in the cortex, and 18 ± 3/ mm2 (TBI)
versus 0/ mm2 (HI) in the cerebellum. These results suggest
that low blood chimerism and reduced expression of
chemoattractants like CCL2 in the brain result in reduced and
delayed engraftment of BMDCs in the HI protocol.
Enhanced recruitment of myeloid cells to sites of brain
damage
We next tested whether HI in combination with neuronal
damage accelerates the recruitment of BMDCs to the brain. To
this end, we performed facial nerve axotomy in chimeric mice,
which results in motoneuron degeneration in the absence of
blood-brain barrier disruption [6]. Given that some potential
precursors of brain macrophages, such as bone marrow-
derived Ly6Chi inflammatory monocytes [21] or Cx3CR1+
progenitors [5], do not self-renew and have a short life span in
the blood stream, we performed FNA one day before BMT
(Figure 3A). HI was carried out 14 days prior to transplantation
to match the peak of chemokine/cytokine expression after
irradiation (cf. Figure 1B) with the time points of analysis at 7
and 14 days after BMT (i.e. 3 and 4 weeks after irradiation).
For comparison, we also used the chemotherapeutic agent
busulfan for conditioning (Figure 3A). Busulfan has recently
been demonstrated to trigger the entry of BMDCs into the brain
with reduced CNS inflammation [24]. Mice receiving either HI
or FNA alone prior to BMT served as control groups (Figure
3A).
As expected given the myelotoxic properties of busulfan, HI
treatment resulted in lower blood chimerism compared to
busulfan conditioning (HI + FNA: 5 ± 0.7% versus busulfan +
FNA: 50 ± 4%; Figure 3B). FNA had no impact on blood
chimerism (HI + FNA: 5 ± 0.7% versus HI: 8 ± 1%; Figure 3B),
and conditioning was required to establish blood chimerism
(FNA: <0.5%; Figure 3B). Notably, the vast majority of GFP+
cells in peripheral blood of HI, HI + FNA and busulfan + FNA
chimeras were identified as CD11b+ myeloid cells (> 90% of
GFP+ cells; Figure 3C). These included Ly6Chi monocytes (HI:
8 ± 1%; HI + FNA: 9 ± 1% and busulfan: 10 ± 2% of GFP
+CD11b+ cells; Figure 3C) and Ly6G+ neutrophils (HI: 60 ± 3%;
HI + FNA: 62 ± 2% and busulfan: 67 ± 7.0% of GFP+CD11b+
cells; Figure 3C). No significant differences in the contribution
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of donor-derived myeloid cells were observed between the
groups.
As early as 7 days after BMT, GFP+ cells were specifically
detected in the lesioned facial nucleus of HI + FNA mice (26 ±
7 cells/facial nucleus; Figures 4A,B). These cells were
amoeboid and localized in the brain parenchyma. They were
immunoreactive for Iba-1 and F4/80, which are markers of
macrophages (Figure 4A). At 14 days after BMT, GFP+ cells
with a characteristic ramified morphology and expression of
Iba-1 and F4/80 were detected in the lesioned facial nucleus of
HI + FNA mice (40 ± 12 cells/nucleus, Figures 4A,B). The
unlesioned contralateral facial nucleus was devoid of GFP+
cells at all time points (Figure 4A). Notably, no donor-derived
GFP+ cells were observed in the lesioned facial nucleus of
busulfan + FNA mice at 7 and 14 days after BMT despite high
levels of blood chimerism (Figure 4B). Similarly, FNA and HI
alone also failed to recruit donor-derived myeloid cells into the
lesioned facial nucleus at 7 and 14 days after BMT (Figure 4B).
This is in line with the delayed engraftment kinetics of myeloid
cells after HI treatment (Figures 2B,C), and with published
evidence documenting the necessity of conditioning for myeloid
cell engraftment in the CNS [7,21].
Since myeloid cell recruitment into the CNS has been
suggested to correlate with the induction of CCL2 and CXCL10
mRNAs [21], we used real-time PCR to quantify the expression
levels of both chemokines in the facial nucleus of mice with
FNA, HI and HI + FNA. The expression of CXCL10 and CCL2
mRNAs was potentiated in the HI + FNA group at 14 days after
BMT (Figure 4C). The results suggest that HI and FNA act
synergistically to induce chemokines, which may accelerate the
recruitment of myeloid cells into the CNS.
Discussion
We established a novel non-myeloablative conditioning
protocol for targeting BMDCs to the brain using focal head
Figure 1.  Gene expression profiles of cytokines and chemokines in the brain after HI and TBI.  A) Overview of the
experimental protocol. HI, TBI and Tx denote focal head irradiation, total body irradiation and bone marrow transplantation,
respectively. B) Quantitative real-time PCR of CCL2, CXCL10, CCL5 and TNF-α mRNA expression in brains of HI (grey columns)
and TBI (white columns) animals at 1, 2, 4 and 16 weeks after irradiation and BMT. The mRNA expression levels were normalized
to GAPDH mRNA and compared to naïve mice (fold induction). Reduced cytokine/chemokine mRNA levels were observed in HI
brains compared to the TBI paradigm. Data are means + SEM from 3-5 animals per group. Statistical significance is indicated by
asterisks (*p<0.05; **p<0.01; ***p<0.001).
doi: 10.1371/journal.pone.0080260.g001
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irradiation plus rapamycin. In contrast to TBI or busulfan
treatment, this conditioning regimen minimally disturbs the
host’s hematopoietic system and enables rapid transmigration
of adoptively transferred myeloid cells into the CNS.
BMDCs have emerged as promising treatment vehicles in
neurological and psychiatric disorders [6,14,18,19,22,23].
However, the transmigration of BMDCs into the brain is tightly
regulated. In animal models, in which peripheral blood
chimerism was obtained by parabiosis, no engraftment of
Figure 2.  Delayed engraftment of BMDCs after HI.  A) Flow cytometric analysis of GFP expression in peripheral blood
leukocytes of HI and TBI chimeras. The level of chimerism was significantly lower in HI compared with TBI animals at 16 weeks
after transplantation. Data are means + SEM from 3-5 animals per group. Statistical significance is indicated by the asterisk
(****p<0.0001). B) Quantification of BMDC engraftment in the brains of HI and TBI chimeras. Data are expressed as GFP+ cells per
area in three different brain regions (olfactory bulb, cortex and cerebellum) at 16 weeks after BMT. Data are means + SEM from 3-5
animals per group. n.d. = none detected. Statistical significance is indicated by asterisks (**p<0.01; ***p<0.001). C) Representative
laser confocal microscopic images of ramified donor-derived GFP+ cells in the brains of HI and TBI animals at 16 weeks after BMT.
Note that GFP+ cells were restricted to the cortex in the HI group, but distributed throughout the grey and white matter in TBI
animals.
doi: 10.1371/journal.pone.0080260.g002
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BMDCs in the adult brain was observed [4]. Similary, no CNS
engraftment of BMDCs was observed after irradiation with
brain protection [4,21]. In contrast, TBI is a highly effective
conditioning regimen for targeting BMDCs to the rodent brain
[6,24,26].
In the past, TBI has played an important role in patients
undergoing HSC transplantation. However, TBI may result in
serious acute graft-versus-host disease (GVHD) causing
transplant-related morbidity and mortality, as well as damage to
non-target tissues, which may predispose to GVHD or enhance
the clinical manifestations of acute GVHD [28-30]. Targeted
irradiation with selective delivery of myeloablative doses to
bone and marrow resulted in reduction of tissue damage and
allowance for dose escalation compared with conventional TBI
[28]. Thus, focal irradiation may serve as an alternative
regimen for host conditioning that causes less irradiation/
transplant-related morbidity and mortality. Furthermore, the
availability of a computed tomography (CT) image-guided
radiotherapy, such as helical tomotherapy, provides the
opportunity to deliver highly conforming dose distributions to
complex target shapes while simultaneously avoiding
excessive doses to critical normal tissue [28].
In this study, we established a conditioning protocol in mice
using targeted head irradiation that induced comparatively low
inflammatory responses in the CNS despite cranial radiation
doses which were identical to TBI. Moreover, HI minimally
perturbed the host’s hematopoietic compartment. In contrast to
TBI and busulfan chemotherapy, the HI regimen achieved very
low chimerism in peripheral blood. Nevertheless, HI
conditioning enabled rapid and selective recruitment of myeloid
cells to sites of brain damage. Note that HI alone did not trigger
any CNS engraftment of BMDCs in the absence of additional
Figure 3.  Blood chimerism in HI- and busulfan-conditioned mice with FNA.  A) Overview of the experimental protocol. HI, FNA
and Tx denote focal head irradiation, facial nerve axotomy and bone marrow transplantation, respectively. B) Flow cytometry of
GFP expression in peripheral blood CD45+ cells at 2 weeks after BMT. The level of chimerism was significantly higher in the
busulfan + FNA group compared with the HI + FNA group. FNA had no impact on blood chimerism. Data are means + SEM from
3-5 animals per group. Statistical significance is indicated by asterisks (****p<0.0001). C) Flow cytometric characterization of GFP-
expressing cells in peripheral blood at 2 weeks after BMT. The vast majority of GFP+CD45+ cells express CD11b (>90%). Gating of
this cell population reveals predominantly CD115+Ly6ChiLy6G- monocytes and CD115-Ly6C+Ly6G+ neutrophils. Data are means +
SEM from 3-5 animals per group. n.d. = none detected. No statistical differences were observed between the groups.
doi: 10.1371/journal.pone.0080260.g003
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Figure 4.  Selective engraftment of donor-derived myeloid cells in the lesioned facial nucleus after HI.  A) Identification of
GFP+ myeloid cells in the lesioned facial nucleus of HI chimeras at 7 and 14 days after BMT. Note the increase in F4/80
immunoreactivity at day 14 compared with day 7, indicating increased inflammation. The contralateral unlesioned facial nucleus is
devoid of donor-derived GFP+ cells and shows minimal F4/80 immunoreactivity. Laser confocal microscopic images of areas of
interest (white squares) are shown at increasing magnifications (scale bars: 100 µm – 25 µm). Seven days after BMT, amoeboid
GFP+F4/80+ and GFP+Iba-1+ cells were detected in the lesioned facial nucleus. At 14 days after BMT, GFP+F4/80+ and GFP+Iba-1+
cells in the lesioned facial nucleus were highly ramified. All donor-derived GFP+ cells expressed the macrophage markers, F4/80
and Iba-1. Nuclei were counterstained with DAPI. B) Quantification of myeloid cell engraftment in the lesioned facial nucleus at 7
and 14 days after BMT in FNA, HI, HI + FNA and busulfan + FNA animals. Note that donor-derived GFP+ cells were only detected in
HI + FNA mice. Data are means + SEM from 3-5 animals per group. n.d. = none detected. C) Quantitative real-time PCR of CXCL10
and CCL2 mRNA expression in the facial nucleus of animals with FNA (white bars), HI (grey bars) and HI + FNA (black bars) at 14
days after BMT. The mRNA expression levels were normalized to GAPDH mRNA and compared to naïve mice (fold induction).
Increased chemokine mRNA levels were observed in the facial nucleus of HI + FNA mice compared to HI animals. Data are means
+ SEM from 3-5 animals per group. Statistical significance is indicated by asterisks (*p<0.05).
doi: 10.1371/journal.pone.0080260.g004
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brain damage. Engraftment occurred with a short latency after
BMT (7 days). In contrast, busulfan treatment failed to target
myeloid cells to the CNS within 14 days after BMT. Although
myeloablative chemotherapy with busulfan is often used
clinically in allogeneic HSC transplantation, the effectiveness of
busulfan conditioning in triggering BMDC recruitment to the
rodent brain remains controversial. Lampron et al. did not
observe any donor-derived cells in the CNS after the
administration of 80 mg/kg of busulfan plus 200 mg/kg
cyclophosphamide before BMT [26]. Other reports showed
reduced [24,31] or enhanced [32] BMDC engraftment
compared with TBI using 80 mg/kg, 90 mg/kg and 125 mg/kg of
busulfan, respectively. In our study, the myelosuppressive dose
of 100 mg/kg busulfan failed to rapidly target BMDCs to the
CNS within the first two weeks after BMT.
In order to prevent transplant rejection, we administered the
immunosuppressant drug, rapamycin, in the FNA, HI, HI+FNA
and busulfan+FNA groups. Thus, the differences in CNS
engraftment of BMDCs between the groups cannot be
attributed to rapamycin. Moreover, rapamycin has been used to
stabilize the blood-brain barrier [33].
Cytokines and chemokines are among the signals which may
mediate the transmigration of BMDCs into the brain. Notably,
TBI and busulfan treatment were found to induce CCL2,
CXCL10, CCL3, CCL5, TNF-α and IL-1 gene expression in the
murine brain [21,24,32]. We observed that HI induces the same
pattern of cytokines/chemokines, but to a much lower degree
than TBI. CCL2 is de novo expressed in facial motoneurons
after axotomy [34]. Interestingly, HI increases CCL2 mRNA
expression in the axotomized facial nucleus, which may trigger
myeloid cell engraftment.
The receptor for CCL2, CCR2, was suggested to be
necessary for the egression of monocytes from the bone
marrow (BM) to the spleen [35] and from the blood stream to
the tissue [36], including the brain [21]. Results obtained in
chimeric mice generated by TBI and transplantation of CCR2-
deficient BM cells suggested that BM-derived myeloid cells in
the adult brain originate from circulating Ly6ChiCCR2+
inflammatory monocytes [21]. In contrast, using parabiotic
mice, Ajami et al. showed that the progenitors of BM-derived
myeloid cells in the brain do not spontaneously enter the blood
stream, but need to be artificially administered into the
circulation. The authors proposed HSCs and CX3CR1+
myelomonocytic progenitors (a mixture of non-self-renewing
progenitor populations) as sources of microglia and brain
macrophages, respectively [4,5]. However, these results were
based on hematopoietic reconstitution of the TBI recipients by
transplantation of partially purified BMDCs. Since selective
transplantation of purified BMDC populations is not possible in
a myeloablative setting, the precise characterization of the
precursors of brain myeloid cells has posed a significant
challenge. The optimized conditioning and transplantation
regimen presented in this study allows for the first time to
adoptively transfer selected BMDC populations into wild-type
recipients and to perform short-term analysis of the
transmigration of BMDCs into the CNS without hematopoietic
reconstitution. Thus, the HI protocol provides a valuable tool for
tracking the fate of short-lived BMDCs and for identifying the
precursors of brain macrophages, a promising cell population
for the treatment of neurodegenerative disorders.
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2.1.3. Masuda T*, Sankowski R*, Staszewski O*, Böttcher C, Amann L, Sagar, Scheiwe 
C, Nessler S, Kunz P, van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, 
Gold R, Grün D, Priller J, Stadelmann C, Prinz M.  
 Spatial and temporal heterogeneity of mouse and human microglia at single-cell 
resolution. 
   Nature. 566:388-392 (2019). 
https://doi.org/10.1038/s41586-019-0924-x 
 
The study used multiple advanced techniques including single-cell RNA sequencing (scRNA-Seq), 
single-molecule FISH, immunohistochemistry and computational modelling to comprehensively 
characterize microglial heterogeneity both spatially and temporally. To investigate the single-cell 
transcriptional profiles, microglia were isolated from different regions of embryonic, juvenile and 
adult mouse brains. Transcriptomic landscapes were comparatively analysed using scRNA-Seq 
technique. The results demonstrated spatial and temporal heterogeneity of microglia across 
developmental stages. The transcriptomic landscape of microglia isolated from cerebellum was 
comparable over the course of development. In contrast, the microglial signatures elucidated in the 
cortex and hippocampus were different between embryonic and postnatal microglia. For example, 
the CST3+SPARC+IBA1+ microglia subpopulation was prominent in the cortex of the postnatal 
brain, whereas the embryonic forebrain lacked of this population. The major microglial subset in 
embryonic forebrain was negative for both CST3 and SPARC expression. During demyelination 
and remyelination, disease-dependent microglial transcriptomic signatures were characterized by 
an induction of mRNA expression of Apoe, Axl, Igf1, Lyz2, Itgax, Gpnmb and Apoc1. Subsets that 
associated with demyelination (SPP1+CD74−IBA1+ and TMEM119−CD74−IBA1+) and 
remyelination (SPP1−CD74−IBA1+ and TMEM119−CD74+IBA1+) were identified. Analysis of 
human microglial signatures revealed similarities with gene expression profiles of mouse microglia 
in the homeostatic brain. However, different gene expression profiles between species were also 
identified, including the expression of Ccl4 mRNA in human microglia but not in mouse cells. In 
the brains of patients with multiple sclerosis, disease-associated microglial subpopulations, which 
were distinct from homeostatic microglia, were identified. These particular microglial subtypes 
showed increased expression levels of APOE, MAFB, CTSD, APOC1, GPNMB, ANXA2, LGALS1, 
CD74, SPP1 and HLA-DR, while microglial homeostatic markers such as TMEM119 were strongly 
reduced. The findings suggested heterogenous responses and/or regulation of the microglial 
population in the CNS, as well as immunoregulatory functions of microglia during CNS diseases. 
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2.2. Phenotypic and functional characterization of CNS cells utilizing mass spectrometry 
technique  
2.2.1. Böttcher C*, Schlickeiser S*, Sneeboer MAM*, Kunkel D, Knop A, Paza E, 
Fidzinski P, Kraus L, Snijders GJL, Kahn RS, Schulz AR, Mei HE, NBB-Psy, Hol 
EM, Siegmund B, Glauben R, Spruth EJ, de Witte LD*, Priller J*. 
Human microglia regional heterogeneity and phenotypes determined by 
multiplexed single-cell mass cytometry.  
Nat Neurosci. 22:78-90 (2019). 
* These authors contributed equally.          
https://.doi.org/10.1038/s41593-018-0290-2 
 
The cellular complexity of the CNS myeloid compartment has been extensively investigated, both 
in the context of cell ontogeny and phenotypic heterogeneity, as well as in response to brain 
pathology. However, these studies were mostly performed in the rodent models, and thus human 
CNS myeloid cells remained largely unexplored. Although some comparative analyses of the 
transcriptomic landscapes of microglia and CNS myeloid cells revealed similarities between mouse 
and man, species-specific patterns of gene expression, and differences in the responses of human 
and mouse microglia to altered CNS conditions were observed.  
In this study, the comprehensive characterization of microglial phenotypes and regional 
heterogeneity was performed using high-dimensional single-cell cytometry by time-of-flight mass 
spectrometry (mass cytometry or CyTOF). Microglial characteristics were compared with other 
immune cells in the brain including perivascular macrophages. To do so, human microglia (huMG) 
were isolated from different brain regions of post-mortem brain tissues and from fresh brain 
biopsies, and at the same time peripheral immune cells were isolated from peripheral blood and 
cerebrospinal fluid (CSF). Subsequently, the isolated cells were fixed and cryopreserved according 
to a newly established protocol, which allowed for a long-term storage of huMG, which are 
otherwise strongly susceptible to cryopreservation-induced damage. To simultaneously determine 
multiple samples from different individuals and compartments, a cellular barcoding technology 
was applied for multiplexing samples prior to CyTOF analysis. 
Based on the expression of 57 selected markers, human microglial core signature was identified, 
which were distinct from myeloid cells in the peripheral blood and CSF, as well as different from 




Figure 4 Representative two-dimensional t-SNE map of brain mononuclear cells (n = 36). 
Each dot represents one cell. The color spectrum represents expression of P2Y12 (a microglia-
specific marker; red denotes high expression, blue denotes no expression). P2Y12+ cells were gated 
as microglia (red gate) and P2Y12- cells were gated as different infiltrating immune cells (blue gate). 
Heat maps and cluster analysis of all samples based on the mean expression of 57 markers. 
Similarities between PBMCs (blue), CSF cells (orange) and huMG (green), as well as the 
similarities between microglia from different brain regions (SVZ (bright green) = subventricular 
zone; THA (grey) = thalamus; CER (red) = cerebellum; temporal lobe (GTS, bright blue); frontal 
lobe (GFM, dark blue) samples and expression levels are indicated by dendrograms. Heat colours 
of expression levels have been scaled for each marker individually (to the 1st and 5th quintiles), 
while red denotes high and blue low expression. 
 
Post-mortem huMG were phenotypically comparable to fresh biopsy huMG. Using algorithm-
based data analysis, microglia clustered separately from perivascular brain macrophages, another 
cell type of CNS tissue resident macrophages, which are phenotypically very similar to microglia. 
Furthermore, regional heterogeneity of microglia in the human brain was identified. These findings 
are in line with the previous mentioned study (2.1.3.). Four region-dependent microglial 
subpopulations were identified. The microglial subpopulation that is predominantly found in the 
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subventricular zone (SVZ) and thalamus (THA) highly expressed CD11c, CCR5, CD45, CD64, 
CD68, CX3CR1, EMR1 and HLA-DR, whereas cortical microglia expressed higher levels of 
CD206 compared with the other subpopulations. Taken together, the identification of microglial 
heterogeneity in the human brain suggests region-specific functions and/or regional vulnerability 
to brain diseases, and thus encourages the development of the more specific therapeutic approaches 




2.2.2. Boettcher C, Fellermeier M, Boettcher C, Dräger B, Zenk MH. 
How human neuroblastoma cells make morphine.  
Proc Natl Acad Sci USA, 102:8495-500 (2005). 
https://doi.org/10.1073/pnas.0503244102 
 
Dynamic interactions between neurons and non-neuronal cells (in particular microglia) are 
necessary for CNS homeostasis and function. Microglia dynamically regulate neuronal activity and 
synaptic transmission by clearance of cellular and subcellular elements of damaged neurons and/or 
providing factors with trophic or neuroprotective properties, such as BDNF, ATP and glutamate. 
Vice versa, neuronal activity can modulate microglial behavior by secreting for example 
chemokines such as CCL21, CX3CL1. However, the molecular cues that regulate the dynamic 
interaction between both cell populations remain largely unknown, which has previously resulted 
from the lack of high-resolution analytical techniques to reveal dynamic biosynthesis of key 
regulators responsible for the neuron-glial crosstalk. 
In this study, targeted metabolomic analysis was performed in human SH-SY5Y neuroblastoma 
cells, the cell line that was proven to be capable of synthesizing morphine [Poeaknapo et al. 2004]. 
The entire morphine biosynthetic pathway was investigated in SH-SY5Y cells by applying various 
isotope-labelled precursors of morphine including L-[1,2,3-13C3]- and [ring-2´,5´,6´-2H3]-dopa, 
[2,2-2H2]-dopamine, (S)-[1,3,4,-2H3]-norlaudanosoline, [7-2H]-salutaridinol, [7-2H,N-C2H3]-




Figure 5 Schematic representation of stable isotope-resolved metabolomic experiments 
elucidating morphine biosynthesis in SH-SY5Y cells. 
 
Five days after the feeding experiment, isotope-labelled morphine was isolated from SH-SY5Y 
cells and analysed by gas chromatography-tandem mass spectrometry (GC/MS/MS). Based on the 
positions where the applied isotopes incorporated into morphine, 19 chemical steps of morphine 
biosynthesis in human neuroblastoma cells were detected. Unlike morphine biosynthesis in the 
poppy plant, human morphine was synthesized via the tetraoxygenated initial isoquinoline alkaloid 
(S)-norlaudanosoline and not via trioxygenated (S)-norcoclaurine. 
The study demonstrated the feasibility of studying targeted metabolomics in a human 
neuroblastoma cell line using an isotope-labelling approach, and thus serves as a platform for 







The CNS is a highly dynamic compartment with complex cellular networks. Apart from neurons, 
microglia and infiltrated immune cells play crucial roles in the regulation of CNS homeostasis and 
function. Microglia perform dynamic phenotypic and functional changes throughout the lifespan, 
depending upon the cue signals from other CNS cells. Better understanding characteristics of these 
cells and how they interact with each other may lead to more effective strategy for treatment 
development in neurological and psychiatric disorders. 
 
Infiltrating immune cells integrate into the myeloid cell compartment of the retina and the brain 
Adoptive transfer experiments of gene-modified bone marrow-derived cells (BMDCs) in mouse 
models of retinal [selected own works 2.1.1] and brain [selected own works 2.1.2.] degenerations 
performed in this study unequivocally provides evidence for capability of circulating cells from the 
periphery to engraft into the CNS, preferentially into the damage sites. These engrafted cells stably 
integrate into myeloid cell compartment of the CNS and express their transferred gene, even at 
more than one year after adoptive transfer. These findings suggest therapeutic potential of 
circulating cells like transplanted BMDCs as live Trojan horse for delivery of therapeutic gene to 
the damage sites of damage retina and brain. However, circulating cells have been shown to be 
able to trigger neuroinflammation and/or involve in resolution of neuroinflammation in CNS 
diseases [Schwartz & Baruch 2014; Ajami et al., 2011], and hence therapeutic effects of these 
engrafted bone-marrow-derived cells in CNS diseases remain to be precisely evaluated. 
The other concern for clinical application of gene-modified BMDCs is the host-precondition and 
the route of administration, especially an application route for treatment in retinal degenerative 
diseases. Our study in mouse models of retinal degeneration [selected own works 2.1.1] 
demonstrated that BMDCs engrafted only into particular layers of the retina, these were the inner 
(IPL) and outer (OPL) plexiform layers and the ganglion cell layer (GCL). None of them were 
detected in the photoreceptor cell layer, where the degeneration actually occurred, thus an 
alternative route of application remains to be investigated for treatment development. Furthermore, 
in mouse models, total body irradiation (with a lethal irradiation dosage) has been normally applied 
to precondition the host immune system prior to adoptive transfer of gene-modified donor-derived 
cells. It has already been demonstrated that BMDCs were not capable of entering the non-
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conditioned brain, and thus required host-preconditioning [Ajami et al., 2007; Mildner et al., 2007]. 
This precondition leads to systemic collapse of host immunity, which avoids the immune rejection 
of the donor cells. However, this strategy is not a viable option for a clinical application in human 
patients. Herein, an alternative protocol for host-precondition that avoids a complete ablation of 
the host immunity was demonstrated. This non-myeloablative precondition using focal-head 
irradiation effectively targeted the BMDCs from the periphery to the damage brain. Although the 
number of engrafted cells were much lower compared to the classical precondition using lethally 
total body irradiation, the engraftment in this precondition model was more specific and restricted 
to the damage sites. Therefore, it may be used to precisely identify the cell population of BMDCs 
that are capable of entering the CNS. Whether this low number of infiltrating cells would 
effectively result in subtle therapeutic effects also remains further evaluation. 
 
Spatial and temporal heterogeneity of microglia in homeostasis and during brain disease 
Microglia are highly plastic cells. They provide multifaceted effects on neuronal as well as non-
neuronal cells in homeostasis and during disease. In an in vitro environment, microglia can express 
a variety of neuroactive agents that are considered as pathological factors, including TNF-α or 
ligands for chemokine receptors such as CCR1, 3, 5, and 7 and CXCR1 or 3, but they can also 
express trophic factors like brain-derived neurotrophic factor (BDNF), the gaseous transmitter NO 
or neurotransmitters (ATP and glutamate) [Kettenmann et al., 2011; Biber et al., 2001; de Jong et 
al., 2005]. These substances rapidly modulate neuronal function and/or mediate the regulation of 
synapse integrity and plasticity in the healthy brain.  
In the selected own work 2.1.3., we identified the spatial and temporal transcriptomic heterogeneity 
of mouse and human microglia using single-cell RNA sequencing. These findings were in line with 
the previous observations by Grabert et al. [2016], which were shown in the RNA-bulk system 
analysis that, under CNS homeostasis, various microglial subpopulations have different 
characteristics and differential functions in a region-specific manner. During diseases, microglia 
respond to the local inflammation and undergo activation, and thereby can either resolve the 
neuroinflammation or escalate the tissue toxicity and subsequently induce neuronal degeneration. 
In this study (2.1.3.), we showed that disease-associated microglial responses were also temporally 
heterogenous. Early after neurodegeneration induced by facial nerve axotomy, homeostatic 
microglial population rapidly changed their phenotypes to disease-specific signatures, 
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characterized by higher expression of Apoe, Axl, Igf1, Lyz2, Itgax, Gpnmb and Apoc1. At recovery 
phase, strongly reduced microglial activation was observed. Moreover, microglial signatures at this 
late disease phase was comparable to homeostatic signatures, thus confirmed high plasticity of 
microglial population. Similarly, we could also identify disease-specific microglial signatures in 
human patients with multiple sclerosis. However, in this study (2.1.3.), the correlation between 
phenotypic alteration of microglia and the number and phenotypic of infiltrating cells during 
disease remains undiscovered. Since circulating cells have been shown to be able to trigger 
neuroinflammation and/or involve in resolution of neuroinflammation in CNS diseases [Schwartz 
& Baruch 2014; Ajami et al., 2011], investigating the correlation between changes in microglial 
subpopulations and infiltrating cells may lead to better understanding of disease pathogenesis 
and/or regulation. Nonetheless, microglial heterogeneity at the single-cell protein level remains to 
be elucidated.  
 
Elucidating CNS cell phenotype and function using mass spectrometry techniques 
In the selected own work 2.2.1., mass cytometry (CyTOF) was used to simultaneously characterize 
circulating immune cells in the peripheral blood and cerebrospinal fluid, the infiltrating immune 
cells in the brain and the perivascular brain macrophages, in comparison to the parenchymal 
microglia isolated from different brain regions. In this study (2.2.1.), we confirmed unique 
microglial signature, which was distinct from peripheral and infiltrating immune cells. Moreover, 
similar to the selected own work 2.1.3., regional microglial heterogeneity could be confirmed by 
CyTOF analysis. However, it remains to be investigated whether these proteomic signatures of 
microglia can be rapidly altered during disease, as it has been observed at the transcriptomic 
signatures (selected own work 2.1.3.). For the first time, CyTOF allows a comprehensive 
investigation of multiple cell subtypes at the single-cell protein level. Although these results were 
in line with and nicely complement the previously reported transcriptomic profiles in the human 
system, many transcriptomic signatures could not yet be proven, which largely due to the limitation 
of availability of CyTOF antibodies and stable metal isotopes. Adding more antibodies for the 
characterization of other CNS cells such as anti-NeuN antibody for neurons, anti-GFAP and anti-
GLAST antibody for astroglia, or anti-CD31 (or platelet endothelial cell adhesion molecule-1, 
PECAM-a) antibody for endothelial cells can expand the phenotypic spectrum of detected cell 
types. However, finding a validated protocol for simultaneous isolation of all different cell types 
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from the brain tissue or the retina, and optimizing a staining protocol that is suitable for all cell 
types of interest are major challenges of such objectives. Open questions also include the spatial 
characteristics and dynamic crosstalk between each cell population in the CNS. Imaging mass 
cytometry (IMC) has recently become commercially available and may serve as the technique of 
choice for uncovering spatial phenotypic and functional heterogeneity in the CNS, since this 
technique allows multi-parameter profiling of a wide spectrum of cell types on tissue sections using 
the same principle as mass cytometry. In IMC, a total of about 37 markers can be simultaneously 
determined on the brain tissue section [Giesen et al., 2014]. 
Yet phenotypic profiles per se merely outline the characteristics of the cells, whereas metabolomics 
reflect dynamic responses of living cells, which can be rapidly altered to maintain their energy, 
cycling and communication with others in the complex system. Thus, metabolomics reveal gene 
expression products, protein outputs and metabolites/small molecules reflecting their responses to 
environment changes. Exquisitely sensitive methods are required to quantify rare compounds 
whose abundances can change rapidly in a living system. In this study (selected own work 2.2.2.), 
a stable isotope-labelling approach was successfully used for metabolomic analysis of human 
neuronal cells. This methodology can be optimized for in vitro metabolomic studies of other CNS 
cell types, both cell lines and isolated primary cells. Although it is still limited as a bulk system 
analysis, this method complements the results obtained from transcriptomic analysis (such as 
single-cell RNA-sequencing) and phenotypic profiling, for example utilizing mass cytometry. And 
vice versa the transcriptomic analysis and/or phenotypic profiling at the single-cell level can be 
used to identify the targeted metabolites and their precursors a priori. Nonetheless, concerns should 
be taken into account in the context of differential characteristics of the targeted cells in vitro and 
in vivo, which could lead to differences in phenotypes and metabolomics between cells from 
different experimental conditions. 
Perspectively, it is important to further explore this CNS myeloid cell compartment under disease 
conditions along with neurons and other non-neuronal cells in the CNS, how they interact with 
each other, how they response to disease and how they regulate or obliterate CNS homeostasis 
during pathology. In sum, comprehensive analysis using in vivo isotope-resolved metabolomics 
(Figure 6A) and single-cell multiplexed mass cytometry of the isolated CNS cell populations 
(Figure 6B) will provide invaluable information on dynamic interaction between multiple cell 
types in homeostasis and during diseases. The obtained results can be then confirmed, for example, 
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in in vitro isotope-resolved metabolomic experiment with and without co-culturing between 
different cell types (Figure 6C). Although the in vitro system could not completely represent the 
in vivo conditions, it provides possibility to directly study interaction (especially cell-cell 
signalling) between two or more CNS cell population under modified conditions. Finally, to 
achieve subcellular spatial information of dynamic changes detected, imaging mass cytometry 






Figure 6 Suggestive combination of mass spectrometry techniques for simultaneous 
characterization of multiple cell types of the CNS. (A) Isotope labelling can be performed in vivo 
(for example in patients with brain tumour prior to tumour biopsy [Charidemou et al., 2017]). CNS 
cells can be then isolated and analysed for their metabolomic characteristics using mass 
spectrometry. (B) Multiple isolated CNS cell populations including perivascular macrophages, 
microglia, astrocytes and neurons can be directly and simultaneously characterized by mass 
cytometry (CyTOF). (C) Isolated CNS cells can be cultured in vitro for further metabolomic 
characterization using mass spectrometry. Using this experimental approach two or more cell types 
can be co-cultured for further metabolomic analysis. (D) High-dimensional immunohistochemistry 
(for determination of up to 37 markers on one tissue section) of formalin-fixed paraffin embedded 




In sum, this study combined multiple techniques including flow cytometry, immunohistochemistry, 
RT-PCR and mass spectrometry to comprehensively characterize CNS microglia/myeloid cell 
compartment in mouse and man. The findings confirmed the complexity of this cell population in 
the CNS comprising various cell types of both CNS-resident cells and infiltrating immune cells. 
Our results suggested their importance in the regulation of CNS homeostasis. Furthermore, we 
provided herein evidence for possibility to use infiltrating myeloid cells as cellular vehicle to 
deliver therapeutic gene/protein to the sites of brain lesion.  
We demonstrated the power of two mass spectrometry techniques, mass cytometry and stable 
isotope-resolved metabolomics for comprehensive elucidation of CNS cell phenotypes and 
functions, both in in vitro and in vivo system. The combination of both mass spectrometry 
techniques, as well as the novel imaging mass cytometry, for phenotypic and functional elucidation 
will make the leap to unravel complex systems biology of the CNS cellular compartment. In 
addition, beyond the scope of this study, the number of available high-throughput techniques that 
can be applied for simultaneous characterization of various CNS cell populations (such as the 
cutting edge technology of single-cell metabolomics that may make the leap to unravel [Fessenden 
2016]) has already increased. Again, the combination of these techniques is required to provide 
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